FDA Letter Blasts Sri Krishna Over Data Integrity Concerns

Drug GMP Report
A second FDA inspection of niche drugmaker Sri Krishna after almost 10 years has turned up a bevy of complaints regarding the company’s quality control systems and the accuracy of its data.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00